The final part of the Congress will connect the strands of day 1 and consider what can be done. There will be a keynote on how communities can effect change followed by reports from the five Communities of Interest, concluding with a session where attendees will be asked what they want to do, or will do, as a follow-up to the Congress. Attendees will film each other outlining their commitments as part of both the larger Commons community and as part of their Community of Interest. There will then be a closing keynote including a report on the large "game changer" by Stephen Friend.
At the conclusion of the Congress attendees will understand how their own work connects to the greater movement of change in how we must approach biology and how biology relates to health care. Participants will be challenged to articulate how their work from the previous day and over the next year might lead to more sharing, better resource allocation, and faster progress. Participants will have established a set of communities ready to do active work.
President, Co-Founder and Director of Sage Bionetworks. Dr. Friend is the President of Sage Bionetworks. He is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community. Dr. Friend has been a senior advisor to the NCI, several biotech companies, a Trustee of the AACR and is a AAAS and Ashoka Fellow as well as an editorial board memeber of Open Network Biology. Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.